An Improved Route to Guanines Substituted at N-9

Mark Ashwell,[a] Christine Bleasdale,[a] Bernard T. Golding,[a] and Ian K. O'Neill[b]

[a] *Department of Chemistry, The University, Newcastle upon Tyne NE1 7RU, UK*
[b] *Unit of Environmental Carcinogens and Host Factors, International Agency for Research on Cancer, Lyon 69372, France*

2-Amino-6-chloropurines (**2b**)—(**2e**) react with trimethylamine/3-hydroxypropionitrile in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene to afford the corresponding *N*-9-substituted guanines (**1b**)—(**1e**) in near-quantitative yield.

Synthetic procedures leading to *N*-9 substituted guanines in a simple, direct manner are of considerable interest,[1] primarily because of the potential antiviral activity of such derivatives [*e.g.* acyclovir,[2] (**1a**)]. In connection with our studies[3] of a polymer-linked guanine for the *in vivo* trapping and detection of carcinogens we required a synthesis of the guanine derivative (**1b**). We describe an efficient route to the guanine (**1b**) and related compounds (**1c**)—(**1e**), that exhibits the following important features: (i) Conversion of a 2-amino-6-chloropurine into an *N*-9 substituted guanine using trimethylamine/3-hydroxypropionitrile/1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU) in dichloromethane. (ii) Protection of the 2-amino group during procedure (i) using 4,4′-dimethoxytrityl (DMT) tetrafluoroborate. (iii) Conversion of a methyl ester into the corresponding carboxylate under the reaction conditions.

Previous methods for the conversion of 2-amino-6-chloropurines into guanines have mostly utilised vigorous acidic[4] or basic[5] conditions that are not compatible with sensitive functional groups within an *N*-9 substituent. Our method for the conversion of *N*-9 substituted 2-amino-6-chloropurines into *N*-9 substituted guanines preserves acetal and silyl protecting groups in the *N*-9 substituent. The method exploits the well established propensity[6] of 2-cyanoethoxy groups to undergo base-induced elimination of the oxygen function when this is attached to a suitable carrier (*e.g.* P in phosphates). Thus, it is known[7] that 6-chloropurines react with trimethylamine to afford 6-trimethylammonium derivatives, that are susceptible to nucleophilic displacement of the trimethylammonium group.[8] We have found that treatment of 6-chloropurines (**2b**)—(**2e**) with trimethylamine in the presence of 3-hydroxypropionitrile and DBU leads efficiently to the corresponding guanine (**1b**)—(**1e**) (95—98% yield)† *via* intermediate 6-trimethylammonium [*e.g.* (**3a**)] and 6-(2-cyanoethoxy) [*e.g.* (**3b**)] derivatives. The trimethylammonium compound can be isolated in low yield (~50%) from treatment of the 2-amino-6-chloropurine with an excess of trimethylamine. The low yield is presumed to be due to further reaction of the trimethylammonium compound with trimethylamine leading to the observed 6-dimethylamino by-product [*e.g.* (**3c**)].[9] In our system the trimethylammonium compound is trapped by reaction with 3-hydroxypropionitrile faster than its reaction with trimethylamine. The trimethylammonium compound was shown to react with 3-hydroxypropionitrile in the presence of DBU to produce initially the 6-(2-cyanoethoxy) derivative and then the guanine. The conversion of the ester group of (**2b**) into the carboxylic acid of (**1b**) presumably occurs *via* base-catalysed transesterification of the methyl ester to a 2-cyanoethoxy ester, which undergoes DBU-catalysed elimination.[10]

† To the *N*-9 alkylated 2-amino-6-chloropurine (**2b**)—(**2e**) (1 mmol) in dichloromethane (3 ml) containing 3-hydroxypropionitrile (5 mmol) at 0 °C, was added trimethylamine (1 ml) and DBU (1.5 mmol). The mixture was set aside at 4 °C (16 h). The solvent and excess of trimethylamine were removed *in vacuo* at 30 °C. The resulting oil was dissolved in dichloromethane (10 ml), and silica gel added. Removal of the solvent to give a free-flowing solid was followed by chromatography on silica gel to give the guanines (**1b**)—(**1e**) (elution with dichloromethane–methanol, proportion dependent on substrate).

New compounds were chromatographically homogeneous and gave analytical/spectroscopic data in accord with the assigned structures.





(1a) R^1 = H, R^2 = $CH_2OCH_2CH_2OH$ (2a) R^1 = R^2 = H



(1b) R^1 = DMT, R^2 =



(2b) R^1 = DMT, R^2 =



c; R^1 = DMT, R^2 =



d; R^1 = H, R^2 = Et

e; R^1 = H, R^2 = $CH_2CH_2OSiMe_2$

f; R^1 = H, R^2 =



g; R^1 = H, R^2 =



(3)

a; X = N^+Me_3
b; X = $O(CH_2)_2CN$
c; X = NMe_2



(4)

a; R = CO_2Me
b; R = $CH_2OSiPh_2Bu^t$

The 2-amino-6-chloropurines (**2d**) and (**2e**) were prepared by the reaction of 2-amino-6-chloropurine (**2a**) with the appropriate alkylating agent [ethyl toluene-4-sulphonate for (**2d**), 2-bromoethyl dimethylthexylsilyl ether for (**2e**); thexyl = 1,1,2-trimethylpropyl] in dimethylformamide in the presence of potassium carbonate.[4a,11] A similar procedure was used to obtain purines (**2f**) and (**2g**) from (**4a**) and (**4b**), respectively. Purines (**2f**) and (**2g**) were readily converted into (**2b**) and (**2c**), respectively by treatment with 4,4′-dimethoxytrityl tetrafluoroborate/2,6-di-t-butyl-4-methylpyridine in acetonitrile.[12] The use of dimethoxytrityl protection here facilitated chromatographic isolation and purification of guanines (**1b**) and (**1c**) and enables spectroscopic assay of the extent of reaction of (**1b**) with a polymer, by acidic cleavage of the dimethoxytrityl group.

The methods described should be of general utility for the preparation of *N*-9 substituted guanines.

We thank the US National Cancer Institute for financial support of this research (Grant R01 CA 39417-01) and Dr. D. Shuker for helpful discussions.

Received, 9th April 1990; Com. 0/01597K

References

1 M. R. Harnden, S. Bailey, M. R. Boyd, M. Cole, R. L. Jarvest, and P. G. Wyatt, in 'Topics in Medicinal Chemistry, 4th SCI-RSC Medicinal Chemistry Symposium,' ed. P. R. Leeming, Royal Society of Chemistry, London, 1987, p. 213; C. K. Chu and S. J. Cutler, *J. Heterocycl. Chem.*, 1986, **23**, 289.
2 H. J. Schaeffer, L. Beauchamp, P. de Miranda, G. B. Elion, D. J. Bauer, and P. Collins, *Nature*, 1978, **272**, 583.
3 M. Ashwell, C. Bleasdale, B. T. Golding, and I. K. O'Neill, presented at a meeting on 'Biomonitoring and Carcinogen Risk Assessment,' held at Queens College, Cambridge, 27—28 July 1989, proceedings to be published by Oxford University Press.
4 (a) M. R. Harnden, R. L. Jarvest, T. H. Bacon, and M. R. Boyd, *J. Med. Chem.*, 1987, **30**, 1636; (b) M. F. Jones and S. M. Roberts, *J. Chem. Soc., Perkin Trans. 1*, 1988, 2927.
5 W. W. Lee, A. P. Martinez, L. Goodman, and D. W. Henry, *J. Org. Chem.*, 1972, **37**, 2923; K. K. Ogilvie and H. R. Hanna, *Can. J. Chem.*, 1984, **62**, 2702; E. Abushanab and M. S. P. Sarma, *J. Med. Chem.*, 1989, **32**, 76.
6 S. A. Narang, *Tetrahedron*, 1983, **39**, 3.
7 L. R. Lewis, F. H. Schneider, and R. K. Robins, *J. Org. Chem.*, 1961, **26**, 3837; J. Kiburis and J. H. Lister, *J. Chem. Soc.* (*C*), 1971, 3942.
8 B. L. Gaffney and R. A. Jones, *Tetrahedron Lett.*, 1982, **23**, 2253, 2257.
9 *Cf.* J. Kiburis and J. H. Lister, *J. Chem. Soc.* (*C*), 1971, 1587.
10 *Cf.* P. K. Misra, S. A. N. Hashmi, W. Haq, and S. B. Katti, *Tetrahedron Lett.*, 1989, **30**, 3569.
11 A. J. H. Nollett, C. M. Huting, and U. K. Pandit, *Tetrahedron*, 1969, **25**, 5971.
12 C. Bleasdale, S. B. Ellwood, and B. T. Golding, *J. Chem. Soc., Perkin Trans. 1*, 1990, 803.